MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)

被引：0
|
作者：
Burchardt, A. [1 ]
Andorsky, D. J. [2 ]
Schmidt, B. [3 ]
La Rosee, P. [4 ]
Graeven, U. [5 ]
Czuczman, M. [6 ]
Llorente, M. [6 ]
Li, J. [6 ]
Sharman, J. [7 ]
机构：
[1] Justus Liebig Univ Giessen, Giessen, Germany
[2] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA
[3] Hamatoonkol Uberortliche Gemeinschaftspraxis Pasi, Munich, Germany
[4] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany
[5] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol & Gastroenterol, Monchengladbach, Germany
[6] Celgene Corp, Summit, NJ USA
[7] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V608
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [21] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
  • [22] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [23] Pixantrone Dimaleate in Combination With Fludarabine, Dexamethasone, and Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
    Srokowski, Tomasz P.
    Liebmann, James E.
    Modiano, Manuel R.
    Cohen, Gary I.
    Pro, Barbara
    Romaguera, Jorge E.
    Kuepfer, Christine
    Singer, Jack W.
    Fayad, Luis E.
    CANCER, 2011, 117 (22) : 5067 - 5073
  • [24] AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
    Leonard, John
    Gribben, John G.
    Trneny, Marek
    Scheinberg, Phillip
    Kilavu, Nurgul
    Patturajan, Moore
    Fustier, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    DeRoock, I.
    Chee, K.
    O'Donnell, R.
    Quirch, C.
    Reed-Pease, C.
    Tuscano, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
  • [26] A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Marquez-Arreguin, Gabriel
    Othman, Tamer
    Esteghamat, Naseem S.
    Abedi, Mehrdad
    Socola, Francisco Andres
    Tuscano, Joseph M.
    BLOOD, 2024, 144 : 6317 - 6318
  • [27] MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
    Andorsky, David J.
    Cataruozolo, Patricia E.
    Mouro, Jorge L.
    Li, Ju
    Fustier, Pierre
    Foon, Kenneth A.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma
    Othman, Tamer
    Marquez-Arreguin, Gabriel
    Esteghamat, Naseem
    Tuscano, Joseph
    LEUKEMIA & LYMPHOMA, 2024,
  • [29] Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
    Tuscano, Joseph M.
    Dutia, Mrinal
    Chee, Karen
    Brunson, Ann
    Reed-Pease, Christine
    Abedi, Mehrdad
    Welborn, Jeanna
    O'Donnell, Robert T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 375 - 381
  • [30] Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, Luis
    Liebmann, James
    Modiano, Manuel
    Cohen, Gary
    Pro, Barbara
    Romaguera, Jorge
    Stromatt, Scott
    BLOOD, 2006, 108 (11) : 781A - 781A
12345